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Influence of hydralazine on the pharmacokinetics of tauromustine
(TCNU) in mice
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'Clinical Oncologv L'nit, 2Department ofPharmacologs, UniversitY ofBradford, Bradford BD7 JDP, U-K.
Sunuin. Several investigators including ourselves have shown that hydralazine can potentiate the anti-
tumour activity of certain agents against murine tumours probably by manipulating tumour blood flow. In
order to investigate the effects of admrinistration of hvdralazine on systemic and tumour drug concentrations.
we have examined the plasma and tissue pharmacokinetics of the recently developed nitrosourea. Tauromus-
tine (TCNU). The effect of hydralazine on glomerular filtration rate (GFR) in mice was also examined using
inulin single injection plasma clearance. An active dose of TCNU (30 mg kg-') was administered intravenously
into non-tumour bearing NMRI mice or mice bearing MAC 15A or MAC 26 subcutaneous tumours. Plasma
and tissue levels of TCNU were measured by HPLC. Hydralazine significantly increased (P<.005 in all cases)
the AUCs and decreased the plasma clearance of the drug. Inulin plasma clearance was decreased from
0.258 ±0.046 ml min-' to 0.096 ± 0.017 ml min-' (a factor of 2.69) after administration of hydralazine. This
decrease in GFR would explain the increased plasma half-lives of a renally cleared drug. It is likelv that the
increased AUC values are partly responsible for the improved anti-tumour activity of TCNU when
administered with hydralazine. but the impact of these findings on toxicity needs to be established.
It has long been known that perfusion of experimental
tumours can be manipulated by the use of vasoactive agents
(Algire & Legallais. 1951). Since the microenvironment and
achievable drug concentrations in solid tumours are depen-
dent on blood vascular supply. several studies have attempt-
ed to modify the blood flow to tumours for therapeutic
benefit. A number of vasoactive agents have been shown to
alter blood flow to experimental tumours (Hirst & Wood.
1989) but most recent studies have concentrated on the anti-
hypertensive agent hydralazine. which has consistently been
shown to decrease blood flow through experimental tumours
(Stratford et al.. 1988; Chaplin & Acker. 1987: Brown. 1987:
Siemann. 1990. 1991). Hydralazine has been shown to poten-
tiate the anti-tumour effects of Melphalan against the KHT
sarcoma (Stratford et al.. 1988) and the chemotherapeutic
agents chloro-ethyl-cyclohexyl nitrosourea (CCNU) or Mito-
mycin-C against the KHT sarcoma (Siemann. 1991). This
tumour potentiation is thought to be the result of manipula-
tion of tumour blood flow and the improved anti-tumour
activity reported in these publications is accompanied by
only a slight or no increase in host toxicity, thereby giving a
greater therapeutic index resulting in possible therapeutic
benefit. Studies in this laboratory have shown that hydra-
lazine reduces blood flow through a series of experimental
colon tumours (Quinn et al., 1991a) and potentiates the
efficacy of TCNU, Melphalan and ThioTEPA (Quinn et al..
1991b). In addition to its effects on tumour blood flow.
hydralazine is likely to have systemic effects. A preliminary
study by Honess and Bleehen (1991) has demonstrated that
hydralazine reduces the glomerular filtration rate (GFR) in
mice and suggests that this is likely to affect plasma half lives
or toxicity of drugs. The aim of this study therefore is to
confirm whether or not tumour blood flow alone is responsi-
ble for the enhanced anti-tumour activity seen with hydrala-
zine in combination with TCNU. by studying mouse plasma
and tissue distribution.
Materials and methods
Animals
Pure strain NMRI mice (6-8 weeks of age) were used from
our inbred colony. They received CRM Diet (Labsure. Croy-
don. England) and water ad libitum. All animal procedures
were carried out under a Project Licence approved by the
Home Office. London.
Test compounds
Tauromustine (TCNU) was a gift from Leo Pharmacia AB.
Helsingborg. Sweden. It was dissolved in physiological saline
at an appropriate concentration for a designed dose to be
administered in 0.1 ml per 10 gram body weight. Hydralazine
and inulin were purchased from Sigma Chemical Company.
Poole. Dorset, England.
Reagents
All solvents were at HPLC grade (Rh6ne Poulenc. Man-
chester. England) and other reagents were of analytical
grade. The internal standard N-propyl-p-hydroxybenzoate
was purchased from Sigma. Triple distilled water was used
throughout.
Tumour system
The development of several adenocarcinomas of the large
bowel in NMRI mice from primary tumours induced by
prolonged administration of 1-2-dimethyl-hydralazine has
been described previously (Double et al.. 1975: Bibby et al..
1989). MAC 15A ascitic tumour cells (1 x 106) were inoculat-
ed subcutaneously in the flank. Tumour fragments (approxi-
mately 1 x 2 mm) of MAC 26 were implanted subcutaneously
in the flank by the use of a trocar. Tumour bearing animals
were used when tumours achieved an approximate weight of
I g. At this size. tumours have a well established blood
vascular supply (Quinn et al.. 1991b). with MAC 26 tumours
having a better blood supply than MAC 15A.
Drug treatment
TCNU was injected intravenously at a therapeutic dose of
30 mg kg-' body weight (Bibby et al.. 1988) to both non
tumour bearing mice and mice bearing MAC 26 or MAC
15A tumours. In both non-tumour bearers and tumour bear-
ers. hydralazine was given intravenously at a dose of 10 mg
kg-' body weight (Quinn et al.. 1991b). 10 min after the
TCNU. Three mice were used per point for each experiment.
The influence of hydralazine on GFR was measured by inulin
single injection plasma clearance (Muiller-Suur et al.. 1983).
Hydralazine was administered immediately after the inulin by
the same route. Experiments were duplicated with at least
four mice per point.
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Samplepreparation
Blood samples from three mice at each time point were taken
by cardiac puncture under ether anaesthesia and collected
into heparinised tubes containing 0.5 ml acetate buffer (pH4.7)
for TCNU experiments. Samples were centrifuged at 1,500 g
for 10 min. Plasma was removed, stored and frozen at
-20-C until analysis. Tissues and tumours were collected at
the same time and frozen in liquid nitrogen until analysis.
For TCNU extraction samples were homogenised in acetate
buffer (10% weight/volume) to stabilise the TCNU and cen-
trifuged at 2,000 g for 15 min and supernatants were extract-
ed for HPLC analysis. Blood samples for inulin clearance
experiments were collected into heparinised tubes.
Sample extraction and chromatography of TCNU
TCNU was extracted from plasma and tissues using solid
phase chromatography as described by Double et al. (1988).
TCNIU concentrations were measured by reverse phase
HPLC. Detailed methodology is described by Double et al.
(1988).
Pharmacokinetic analysis
The drug concentration vs time curves were fitted to a bi-
exponential equation. (C = A.e-Kt + B.e-K4t) The ordinate
intercept B and elimination rates (KeL and Kel) were cal-
culated using least squares linear regression analysis on the
log (ln) linear phases of the data, elimination rates being
given by the slope of the fitted lines. Half lives (t1) were
calculated from the equation
0.693
A was taken to be C(0) - B where C(0) is the estimated
plasma concentration at t =0. Clearance was estimated from
the equation Cl = dose (per mouse)/AUC assuming as 25 g
mouse. The area under drug concentration vs time curve
(AUC) for plasma, tumour and tissue sample from 0 - the
last time point (t) was calculated using the trapezoid rule.
The remaining area from k-co was taken to be CJlKelp where Cq = concentration at t.
Glomerularfiltration rates
Inulin was injected into non-tumour bearing mice and
measured by the method of Higashi and Peters (1950). This
method is based on the production of an orange red colour
after hydrolysed inulin is reacted with resorcinol in strong
hydrochloric acid. The colour is measured spectrophoto-
metrically at 492 nm. GFR was calculated by assuming GFR
is equivalent to plasma clearance.
Resuts
The influence of hydralazine on the pharmacokinetics of
TCNU in non-tumour bearing mice and mice bearing MAC
15A and MAC 26 subcutaneous tumours is presented in
Table I. Each value is determined from three mice at each
time point. Data for MAC 15A tumour bearers are also
presented graphically in Figure la-e. There is a clear in-
crease in AUC due to an immediate reduction in clearance
following hydralazine treatment in non-tumour bearers.
These observations are duplicated in the two further indepen- dent experiments with tumour bearers. In all tissues with the
exception of MAC 1SA tumours (Figure le) there is an
increase in terminal half life following hydralazine treatment
but even in this group there is a decrease in clearance and
increase in AUC. The largest increase was seen in the MAC
26 tumour (ratio 3.31). There was no effect on peak plasma levels as hydralazine was given 10min after TCNU.
The plasma concentration following a single intravenous
injection ofinulin at doses over the range 250-1,000 mgkg- '
is shown in Figure 2a. Pharmacokinetics of inulin show a
linear relationship between dose and inulin AUC over the
range 250 to 500mglkg-' (Table II) and so further studies
used an intermediate dose of 375 mgkg-'. The effects of
hydralazine (1Omgkg-') on the plasma clearance of inulin
(375 mgkg-') can be seen in Figure 2b. The AUC was
increased from 0.625 ± 0.11 to 1.68 ± 0.35 mg hml-' ( +
I s.d.) after the administration of hydralazine therefore
decreasing plasma clearance from 0.258 ± 0.046 to 0.096 +
0.017 ml min'. This represents a factor of 2.69 ± 0.29.
This study was designed to see whether the previously
reported chemo-potentiation ofhydralazine in MAC tumours
(Quinn et al., 1991b) was due to a vascular shut down
mediated decrease in rate of drug efflux from the tumour.
The increased AUCs seen in this study demonstrate an in-
creased overall exposure of the tumour to the drug and this
is likely to be partly responsible for the improved anti-
tumour responses. Recent work by Honess and Bleehen
(1991) has shown that hydralazine greatly affects blood flow
not only in tumour, but in normal tissue as well. They
compared relative tumour perfusion measured by MRb ext-
raction in KHT tumours and a range of normal tissues in the
mouse. Hydralazine reduced relative tissue perfusion in sub-
cutaneous flank- and intramuscular leg tumours, substantially
reduced relative tissue perfusion in kidney, spleen and liver
for >6h, reduced skin relative tissue perfusion slightly and
increased lung relative tissue perfusion for 30 min. They also
investigated the renal effects ofhydralazine by measuring the
effect of GFR by assaying plasma clearance of 5'Cr labelled
TableI Influenceofhydralazineon thepharmacokinetics ofTCNU aloneorTCNU afteradministration ofHDZ(in
brackets)
C,01 Kp T C? AUCo-c
Experimrent - (h-l (h) Mim-' ghg-
I jqTMb
Plasma 67.0 (71.5)' 1.33 (0.740) 0.521 (0.36) 1.19 (0.56) 10.5 (22.2)'
2 MAC 15A
Plasma 64.2 (63.0)' 2.16 (0.419) 0.321 (1.65) 1.96 (1.10) 6.38 (I 1.4)d
Liver 30.7 (31.9) 0.374 (0.421) 1.85 (1.65) 2.93 (1.77) 4.27 (7.05)
Lung 31.4 (32.4) 0.355 (0.169) 1.95 (4.08) 2.50 (0.91) 5.00 (13.8)
Kidney 37.5 (38.2) 1.71 (0.556) 0.405 (1.25) 3.63 (1.63) 3.44 (7.65)
Tumour 15.2 (19.0) 0.486 (0.719) 1.43 (0.963) 3.20 (1.51) 3.91 (8.26)
3 MAC 26
Plasma 72.0 (72.7)' 0.563 (0.299) 1.23 (2.31) 1.80 (1.10) 6.94 (11.3)d
Liver 40.1 (41.5) 0.200 (0.270) 3.46 (2.57) 4.86 (1.70) 2.57 (7.30)
Lung 29.1 (30.4) 0.696 (0.565) 1.00 (1.23) 4.21 (2.33) 2.97 (5.37) Kidney 40.7 (42.9) 4.25 (0.796) 0.163 (0.87) 3.52 (1.56) 3.55 (8.04)
Tumour 40.6 (39.6) 3.11 (0.270) 0.223 (2.57) 3.13 (0.94) 3.99 (13.2)
'C = dose (per mouse)/AUC - assuming a 25 g mouse; bNon-tumnour bearers; 'g ml-'; "ug hml-'.HYDRALAZINE ON TAUROMUSTINE PHARMACOKINFTICS 349
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Fgwe I Concentration of TCNU in plasma (pg ml-'), tumour
and tissues (Lg g-') of MAC 15A tumour bearing mice treated
with TCNU alone (0) or TCNU plus hydrlazine (0). a,
plasma; b, kidney; c, lung; d, liver; e, tumour. Values shown are
the mean of at least three mice per point± I s.d.
EDTA. It is not surprising then, that the present study
demonstrates that the administration of hydralazie follow-
ing TCNU increases the AUC ofTCNU in both tumour and
normal tissues. Since the hydralazie is given 1Omin after
TCNU it does not incrase peak plasma levels.
The inulin clarance experiment presented here shows that
hydralazine at a dose of l0mg kg' decreases plasma clear-
ance by a factor of 2.69. This impaired kidney function seen
as a decrease in GFR would explain the increased half-lives
of a renally cleared drug whereas the decreased hepatic blood
flow previously reported by Honess and Bleehen (1991),
could have implications for a drug that is hepatically meta-
bolised. TCNU is largely metabolsed in the liver to de-
methylated and de-nitrosated products (Seidegard et al.,
1990), and high levels of these metabolites are found in the
urine. The decrease in GFR would probably decrease the
Fugwe 2 a, Plasma concentration (mgml-') of inulin following
a single intravenous injection of 250mgkg-' (0), 375 mgkg'
(0), 500mglkg-' (A) and I glkg-' ([3). b, Influence of hydra-
lazine (lOmgkg-') on inulin concentration (mgml-') in mouse
plasma following a single injection of inulin (375 mgkg-'), inulin
alone (0), inulin and hydralaine (0). Each point represents the
mean values of at least four mice (±1 s.d.).
Tabe I InulinAUCandclearancevaluesinnon-tumourbearingmice
following a single intravenous injection (mean± I sd.)
Dose mgkg- AUCmghmli' Cl mlmat-]
250 0.360±0.02 0.267±0.022
375 0.625±0.110 0.258±0.046
500 0.748±0.040 0.279±0.014
1,000 3.57±0.75 0.115±0.022
375 + HDZa 1.68±0.35 0.096±0.017
'Received hydralazine (10mgkg-') simultaneously with inu}in.
clearance of these metabolites. As some of these metabolites
are cytotoxic (Hartley-Asp et al., 1988), this could contribute
further to the increased anti-tumour responses. Work is cur-
rently in progress to assess the effects of hydralazine on
TCNU metabolism. Because of the increased exposure of
normal tissues to TCNU, clearly attention must be paid to
the possible increased toxicty associated with vasoactive
drug combination therapy. Although a recent study by
Siemann (1991) has shown enhancement ofchemotherapy by
hydralazne against the KHT sarcoma and the RIF-1 tumour
without an increase in bone marrow toxcity, on going
studies in this laboratory are fully evaluating the therapeutic
potential of vasoactive manipulation of standard
chemotherapeutic drugs, paying particular attention to nor-
mal host toxicity in addition to anti-tumour effects.
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In conclusion, this study has shown that the administration
of hydralazine after TCNU increases the AUC of TCNU in
plasma. tumour and normal tissues but because of the treat-
ment protocol does not increase peak plasma levels. This
increase in AUC is likely to contribute to the increased
anti-tumour effects seen previously. The administration of
hydralazine decreases the GFR in NMRI mice by a factor of
2.69 and this together with other systemic effects will have
implications on drug metabolism and clearance, demonstrat-
ing that altered tumour blood flow is not solely responsible
for the enhanced anti-tumour activity of TCNU in this
system.
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